Etodolac
Acetic Acid Derivatives and Related Substances
- Drug class
- Acetic Acid Derivatives and Related Substances
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 21
- FDA reports (12 mo)
- 116
Overview
Etodolac is an active pharmaceutical ingredient in the Acetic Acid Derivatives and Related Substances group (M01AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 17 | May 22, 2026 |
| GB United Kingdom | MHRA | 2 | May 15, 2026 |
| CA Canada | Health Canada | 2 | March 22, 2025 |
USUnited States· FDA
17 products
Uses
INDICATIONS AND USAGE
Carefully consider the potential benefits and risks of etodolac tablets and other treatment options before deciding to use etodolac tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ).
Etodolac tablets are indicated:
For acute and long-term use in the management of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis For the management of acute pain
How to take
GBUnited Kingdom· MHRA
2 products
Uses
Lodine (etodolac) is indicated for acute or long-term use in rheumatoid arthritis and osteoarthritis.
How to take
CACanada· Health Canada
2 products
Uses
ETODOLAC (Etodolac capsules) is indicated for: acute or long–term use in the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis (degenerative joint disease). For patients with an increased risk of developing cardiovascular and/or gastrointestinal adverse events, other management strategies that do NOT include the use of NSAIDs should be considered first.
See
How to take
Drug interactions
Known interactions involving Etodolac. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 449. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 00125d63-d8d0-46… · revised January 13, 2026 [PDF]
- [2]MHRA (UK) · PL169730021 · revised May 15, 2026
- [3]Health Canada (DPD) · 02231965 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.